Yeah a cash injection down the track would be great to accelerate sales but I'm not sure we will need that much. Other companies have done most of the marketing work for us and our device is already incredibly well known in the ophthalmology community (they all already know about it and its advantages)
Either way, when the time comes, like you say, the share price should be sufficiently high so that a cap raise of $30-50m will have very little dilution (due to a much higher market cap). In the meantime, the company is loaded with cash so not something to be concerned about in the near term
Looking forward to that wine, love a good Grange
Nova Eye Medical (EYE) Discussion, page-580
-
- There are more pages in this discussion • 2,608 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.005(2.04%) |
Mkt cap ! $54.91M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.8¢ | 24.0¢ | $61.84K | 254.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 353553 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 254871 | 2 |
View Market Depth
| Last trade - 15.54pm 30/07/2024 (20 minute delay) ? |
| EYE (ASX) Chart |